Oncology: Clinical Therapy and Diagnosis -> Clinical Diagnosis -> GU 1558

1558 - Impact of Total Body 68Ga-PSMA-11 PET/CT on bone metastasis detection in Prostate Cancer Patients: should we go from Vertex to Toes ? (ID 1299)

Session Name
Prostate/GU Imaging Posters
Speakers
Authors
Presentation Topic
Oncology: Clinical Therapy and Diagnosis -> Clinical Diagnosis -> GU
Presentation Number
1558

Previous Eposter
1556 - Test-retest study of tumor blood flow quantification with 82Rubidium-PET/CT in prostate cancer (ID 1297)

Next Eposters
1561 - [18F]Fluciclovine PET/MRI for Initial Staging of High-Risk Prostate Cancer (ID 1302)
1563 - Comparison of three interpretation criteria of 68Ga-PSMA PET based on inter- and intra-reader agreement (ID 1304)
1565 - Characterization of Segmented 18F-DCFPyL PET/CT Lesions in the Context of PSMA-RADS Structured Reporting (ID 1306)
1567 - Histologically-confirmed diagnostic efficacy of 18F-rhPSMA-7 positron emission tomography for N-staging of patients with high risk primary prostate cancer (ID 1308)
1571 - COMPARISON OF 68Ga-PSMA PET-CT WITH CONVENTIONAL IMAGING IN LOCALIZATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER (ID 1312)
1573 - Prospective evaluation of18F- DCFPyL in Patients with Biochemically Recurrent Prostate Cancer: Positivity Rate and Correlation with PSA levels (ID 1314)
1576 - [18F]-fluciclovine positivity rate is not affected by androgen deprivation therapy (ADT) in recurrent prostate cancer post-prostatectomy. (ID 1317)
1579 - The role of 68Ga-PSMA-PET/CT after a negative 18F-Choline PET/CT in biochemical relapse of prostate cancer: Initial experience (ID 1320)
1580 - [18F] fluciclovine PET/CT is superior to conventional imaging in preoperative nodal staging in patients with high-risk prostate cancer
(ID 1321)
1581 - Will next-generation PET lead to revised criteria for castration resistant prostate cancer? (ID 1322)